Jamie Olsen, DO
Urology · Dakota Dunes, SDNPI 1518300573
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $805 and has fallen 51.2% since, to $392 in 2025.
Across 155 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$454
- Procept Biorobotics Corporation$349
- EDAP Technomed Inc$318
- Axonics, Inc.$297
- AbbVie$237
- Urogen Pharma, Inc.$227
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$150%
- Food & beverage$3,68598%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 23 | $454 |
| Procept Biorobotics Corporation | 3 | $349 |
| EDAP Technomed Inc | 4 | $318 |
| Axonics, Inc. | 8 | $297 |
| AbbVie(2 entities) | 14 | $237 |
| Urogen Pharma, Inc. | 5 | $227 |
| Boston Scientific | 10 | $221 |
| Myovant Sciences Inc. | 21 | $185 |
| Calyxo, Inc. | 2 | $150 |
| 180 Medical, Inc. | 7 | $130 |
| Terumo Medical Corporation | 1 | $117 |
| Medtronic | 3 | $106 |
| Johnson & Johnson | 7 | $92 |
| Bayer | 5 | $91 |
| Neotract Inc. | 2 | $83 |
| Pfizer | 6 | $82 |
| Merck | 4 | $73 |
| Tolmar Pharmaceuticals, Inc. | 4 | $54 |
| Coloplast | 1 | $54 |
| Teleflex LLC | 3 | $52 |
| Endo Pharmaceuticals Inc. | 3 | $42 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Dendreon Pharmaceuticals LLC | 2 | $40 |
| AstraZeneca | 2 | $36 |
| Amgen | 2 | $29 |
| Dornier Medtech America, Inc | 1 | $29 |
| Ferring Pharmaceuticals Inc. | 2 | $28 |
| Novartis | 1 | $22 |
| Sanofi | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Abbott | 1 | $16 |
| Photocure Inc | 1 | $16 |
| BD | 1 | $15 |
| Olympus America Inc. | 1 | $15 |
| KARL Storz Endoscopy-america | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$260
- CVAC Aspiration System$137
- JELMYTO$133
- Navicross$117
- HydroPearl$117
- Axonics$111
How this compares
$3,755 in reported general payments places this provider in the 85th percentile of 40 urology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 56 | $786,279 |
| XtandiEnzalutamide | 40 | $524,265 |
| NubeqaDarolutamide | 11 | $132,057 |
| OrgovyxRelugolix | 53 | $127,749 |
| Abiraterone Acetate | 39 | $76,148 |
| MyrbetriqMirabegron | 90 | $55,283 |
| GemtesaVibegron | 38 | $23,398 |
| Tamsulosin Hcl | 513 | $5,033 |
| Oxybutynin Chloride ErOxybutynin Chloride | 160 | $3,507 |
| Estradiol | 30 | $2,337 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 27 | $1,713 |
| Trospium Chloride | 42 | $1,596 |
| Solifenacin Succinate | 73 | $1,322 |
| Finasteride | 110 | $955 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 40 | $823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $92 | $786,27956 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $454 | $579,548130 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $42 | $151,14791 claims |
| BayerNubeqa | $91 | $132,05711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 40 urology providers in South Dakota.
Other urology in Dakota Dunes
- Andrew BourneDakota Dunes$6K
- Daniel OlsenDakota Dunes$3K
- David DanielsDakota Dunes$3K
- Adam AlthausDakota Dunes$3K
- Timothy KneibDakota Dunes$3K
- Patrick HonnerDakota Dunes$1K
- Kenneth McCallaDakota Dunes$143
- John WolpertDakota Dunes$95
- David HowardDakota Dunes$83
- Patrick WalshDakota Dunes$53
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.